China Medical Collaborates to Grow - Analyst Blog
24 Juni 2011 - 4:09PM
Zacks
China Medical Technologies, Inc. (CMED), a
Chinese in-vitro diagnostic firm, recently revealed that its whole
subsidiary – Beijing GP Medical Technologies Co. Ltd. ("GP
Medical") has agreed to collaborate with Gaoxin Da An Healthcare
Investment Ltd. ("Da An Health") and jointly market and promote
molecular diagnostic know-how for clinical diagnostic applications
in China.
The two partners will work to introduce novel molecular
diagnostic products to serve Da An Health's hospital clients and
leverage Da An Health's network of labs for validation of new
products. The agreement includes provisions for expanding the scope
of the agreement from molecular diagnostic products to the entire
product lineup of GP Medical.
The Chairman and CEO of China Medical Technologies stated that
the collaboration will lead to greater brand recognition and
product awareness among a fresh clientele. In addition, the company
could get a better idea of hospital demand, which would help in its
product development program.
The CEO of Da An Health observed that Chinese molecular
diagnostic business promises significant growth. By engaging in
joint efforts, the combined entity will cater to a greater number
of healthcare organizations in China.
Gaoxin Da An Healthcare Investment Ltd. is a China-based
company, working on clinical diagnostic testing services and
stand-alone lab service network. It has eight clinical test
facilities catering to a large number of hospitals (Tier 1, Tier 2,
Tier 3 and community hospitals). Da An Health has a fairly strong
independent lab service network in China, providing diagnostic
testing, healthcare screening and associated services.
China Medical Technologies, a leading in-vitro diagnostic
company, based in China, utilizes molecular diagnostic know-how,
such as Surface Plasmon Resonance, Fluorescent in situ
Hybridization and an immuno-diagnostic know-how, to produce
diagnostic products that are most useful for detecting cancers and
other diseases.
China Medical Technologies dominates the market in China and all
its sales generates there. China Medical Technologies competes with
Abbott Laboratories (ABT) and Beckman
Coulter Inc. (BEC), among others, in certain niches.
ABBOTT LABS (ABT): Free Stock Analysis Report
BECKMAN COULTER (BEC): Free Stock Analysis Report
CHINA MED TECH (CMED): Free Stock Analysis Report
Zacks Investment Research
Beckman Coulter (NYSE:BEC)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Beckman Coulter (NYSE:BEC)
Historical Stock Chart
Von Jan 2024 bis Jan 2025